傳遭主要股東減持藥明巨諾(02126.HK)挫10%曾失27元 市前有2,300萬股折讓8.1%上板
有指遭主要股東大手減持的藥明巨諾(02126.HK)今早市前有一宗2,300萬股以每股28.5元(傳聞配售價下限)非自動對盤上板。該股今早一舉跌破10天、20天及50天線(28.35-29.8元),最多急挫13%低見26.9元喘定,現造27.85元,急挫10%,失守配股價,成交增至3,620萬股,涉資10.28億元。
外電引述銷售文件指,藥明巨諾主要股東藥明康德(02359.HK)擬以每股28.5-29.15元(較昨天收市價折讓6%-8.1%),配售2,300萬股,套現最多6.7億元。
藥明康德也由收市紀錄高位反覆回吐2%報180元。(sz/u) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.